Shattuck Labs Extends Cash Runway to 2029, Advances SL-325 to Phase 2, and Raises $26.8M

summarizeSummary

Shattuck Labs reported a widened Q1 net loss but significantly extended its cash runway into 2029 through successful ATM sales and warrant exercises, while also advancing its lead clinical candidate, SL-325, to Phase 2.

check_boxKey Events

• Q1 2026 Financial Results

  Shattuck Labs reported a net loss of $14.8 million for Q1 2026, widening from $13.7 million in Q1 2025. Net loss per share improved to $(0.13) from $(0.27) due to a higher weighted-average share count.

• Cash Runway Extended to 2029

  Management believes current cash and cash equivalents of $90.4 million are sufficient for at least the next 12 months. Critically, assuming full exercise of outstanding common stock warrants, the company projects its cash runway will extend into 2029.

• Successful Capital Raises

  The company raised $21.4 million by selling 5,000,000 shares through its At-The-Market (ATM) facility at an average price of $4.28 per share. Additionally, $5.4 million was generated from the exercise of common stock warrants.

• Clinical Pipeline Progress

  The Phase 1 clinical trial for lead product candidate SL-325 is expected to complete in Q2 2026, with a Phase 2 clinical trial in Crohn's Disease planned for initiation in Q3 2026.

auto_awesomeAnalysis

Shattuck Labs' Q1 2026 report, while showing a widened net loss, delivers critical positive updates for a clinical-stage biotechnology company. The most significant development is the projected extension of its cash runway into 2029, contingent on the full exercise of outstanding common stock warrants. This substantially de-risks the company's near-term funding requirements. The company successfully raised $21.4 million through its At-The-Market (ATM) facility at an average price of $4.28 per share, which, while dilutive and below the current market price, provides essential capital. An additional $5.4 million was generated from common stock warrant exercises. Furthermore, the company announced plans to complete the Phase 1 clinical trial for its lead candidate, SL-325, in Q2 2026 and initiate a Phase 2 trial in Crohn's Disease in Q3 2026, marking important progress in its pipeline development. These combined factors indicate improved financial stability and clinical momentum.